Literature DB >> 19162005

Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.

Matthew Fosbrink1, Cornelia Cudrici, Cosmin A Tegla, Kateryna Soloviova, Takahiro Ito, Sonia Vlaicu, Violeta Rus, Florin Niculescu, Horea Rus.   

Abstract

Proliferation of vascular endothelial cells (EC) and smooth muscle cells (SMC) is a critical event in angiogenesis and atherosclerosis. We previously showed that the C5b-9 assembly during complement activation induces cell cycle in human aortic EC (AEC) and SMC. C5b-9 can induce the expression of Response Gene to Complement (RGC)-32 and over expression of this gene leads to cell cycle activation. Therefore, the present study was carried out to test the requirement of endogenous RGC-32 for the cell cycle activation induced by C5b-9 by knocking-down its expression using siRNA. We identified two RGC-32 siRNAs that can markedly reduce the expression of RGC-32 mRNA in AEC. RGC-32 silencing in these cells abolished DNA synthesis induced by C5b-9 and serum growth factors, indicating the requirement of RGC-32 activity for S-phase entry. RGC-32 siRNA knockdown also significantly reduced the C5b-9 induced CDC2 activation and Akt phosphorylation. CDC2 does not play a role in G1/S transition in HeLa cells stably overexpressing RGC-32. RGC-32 was found to physically associate with Akt and was phosphorylated by Akt in vitro. Mutation of RGC-32 protein at Ser 45 and Ser 47 prevented Akt mediated phosphorylation. In addition, RGC-32 was found to regulate the release of growth factors from AEC. All these data together suggest that cell cycle induction by C5b-9 in AEC is RGC-32 dependent and this is in part through regulation of Akt and growth factor release.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19162005      PMCID: PMC2699899          DOI: 10.1016/j.yexmp.2008.12.005

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  33 in total

Review 1.  CDK inhibitors: positive and negative regulators of G1-phase progression.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1999-06-15       Impact factor: 11.361

Review 2.  Angiogenesis in atherogenesis.

Authors:  Joerg Herrmann; Lilach O Lerman; Debabrata Mukhopadhyay; Claudio Napoli; Amir Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-06-22       Impact factor: 8.311

3.  Glucocorticoid-induced changes in the global gene expression of lens epithelial cells.

Authors:  Eric R James; Victor M Fresco; Lorie L Robertson
Journal:  J Ocul Pharmacol Ther       Date:  2005-02       Impact factor: 2.671

4.  CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis.

Authors:  Eyal Sagiv; Lorenzo Memeo; Adi Karin; Diana Kazanov; Jasmin Jacob-Hirsch; Mahesh Mansukhani; Gidi Rechavi; Hanina Hibshoosh; Nadir Arber
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

5.  RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase.

Authors:  Tudor Badea; Florin Niculescu; Lucian Soane; Matthew Fosbrink; Hila Sorana; Violeta Rus; Moon L Shin; Horea Rus
Journal:  J Biol Chem       Date:  2001-10-30       Impact factor: 5.157

Review 6.  Vascular endothelium and atherosclerosis.

Authors:  P Libby; M Aikawa; M K Jain
Journal:  Handb Exp Pharmacol       Date:  2006

7.  Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD.

Authors:  S Hila; L Soane; C L Koski
Journal:  Glia       Date:  2001-10       Impact factor: 7.452

8.  C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1.

Authors:  Matthew Fosbrink; Florin Niculescu; Violeta Rus; Moon L Shin; Horea Rus
Journal:  J Biol Chem       Date:  2006-05-02       Impact factor: 5.157

Review 9.  Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells.

Authors:  F Niculescu; H Rus
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

10.  Role of response gene to complement 32 in diseases.

Authors:  Sonia I Vlaicu; Cornelia Cudrici; Takahiro Ito; Matthew Fosbrink; Cosmin A Tegla; Violeta Rus; Petru A Mircea; Horea Rus
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-03-31       Impact factor: 4.291

View more
  37 in total

1.  Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration.

Authors:  Jia-Ning Wang; Ning Shi; Wei-Bing Xie; Xia Guo; Shi-You Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-02       Impact factor: 8.311

Review 2.  The role of complement system in adipose tissue-related inflammation.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Dallas Boodhoo; Stefan Vesa; Petru A Mircea; Horea Rus
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

3.  Uncovering the Role of Sox2 in Oligodendroglia.

Authors:  Kristina Kuhbandner
Journal:  J Neurosci       Date:  2018-05-09       Impact factor: 6.167

4.  RGC-32 Deficiency Protects against Hepatic Steatosis by Reducing Lipogenesis.

Authors:  Xiao-Bing Cui; Jun-Na Luan; Shi-You Chen
Journal:  J Biol Chem       Date:  2015-07-01       Impact factor: 5.157

5.  RGC32 deficiency protects against high-fat diet-induced obesity and insulin resistance in mice.

Authors:  Xiao-Bing Cui; Jun-Na Luan; Jianping Ye; Shi-You Chen
Journal:  J Endocrinol       Date:  2014-11-10       Impact factor: 4.286

Review 6.  Membrane attack by complement: the assembly and biology of terminal complement complexes.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Snehal Patel; Richard Trippe; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

7.  RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.

Authors:  Adam M Kruszewski; Gautam Rao; Alexandru Tatomir; Daniel Hewes; Cosmin A Tegla; Cornelia D Cudrici; Vingh Nguyen; Walter Royal; Christopher T Bever; Violeta Rus; Horea Rus
Journal:  Exp Mol Pathol       Date:  2015-09-25       Impact factor: 3.362

Review 8.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

9.  Epigenetic modifications induced by RGC-32 in colon cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Matthew Fosbrink; Vingh Nguyen; Philippe Azimzadeh; Violeta Rus; Hegang Chen; Petru A Mircea; Abulkalam Shamsuddin; Horea Rus
Journal:  Exp Mol Pathol       Date:  2009-10-31       Impact factor: 3.362

Review 10.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.